Welcome to our dedicated page for OSR Health SEC filings (Ticker: OSRHW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on OSR Health's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into OSR Health's regulatory disclosures and financial reporting.
OSR Health, Inc. reported that Nasdaq, in a verbal communication, stated the company’s Shareholder Loyalty Contingent Value Rights (CVR) program will not cause any mechanical adjustment to the price of its common stock, either when CVRs are distributed or when additional shares are delivered to enrolled holders.
Under this loyalty CVR program, shareholders of record on August 14, 2026 who enroll receive one CVR for each share of OSRH common stock and may receive additional shares at no cost if specified closing-price thresholds are met on four measurement dates over the following twelve months. Nasdaq’s view applies only to price-adjustment mechanics and is not an endorsement; the CVR distribution and share deliveries remain subject to separate securities-law and regulatory processes.
OSR Health, Inc. is calling a virtual annual meeting on August 7, 2026 at 10:00 a.m. Eastern Time to vote on four proposals. Holders of 35,118,692 shares of common stock outstanding as of July 8, 2026 may vote to re-elect seven directors, ratify RSM Korea as auditor, approve an advisory Say‑on‑Pay resolution on 2025 executive compensation, and increase authorized common stock from 100,000,000 to 250,000,000 shares.
The Board cites flexibility for a proposed shareholder loyalty program, future financings, strategic transactions and general corporate purposes as reasons for the share increase, while acknowledging potential dilution and possible anti-takeover effects. As of June 30, 2026, CEO Kuk Hyoun Hwang beneficially owned 13,069,106 shares, or 36.8% of common stock, giving him significant influence. In 2025 he received $400,000 in salary; the CSO and CFO received $345,000 and $300,000, respectively. A 2025 Omnibus Incentive Plan reserves 6,300,000 shares for future equity awards, though no stock-based grants had been made by year-end.
OSR Health, Inc., formerly OSR Holdings, Inc., has changed its corporate name to OSR Health, Inc. effective June 11, 2026. The change was approved by the board of directors and implemented through a Certificate of Revival of Charter filed under Delaware corporate law.
The filing of the Certificate of Revival renewed and revived the company’s certificate of incorporation, and the company is in good standing with the Delaware Secretary of State. No other provisions of the certificate of incorporation were amended, and the terms of the common stock and redeemable warrants remain unchanged.
The company’s common stock and warrants continue to trade on The Nasdaq Stock Market LLC under the symbols OSRH and OSRHW, respectively. Stockholders and warrant holders do not need to exchange or surrender existing certificates as a result of the name change.
OSR Holdings, Inc. has postponed its 2026 Annual Meeting of Stockholders. The meeting had been scheduled for June 18, 2026, but the Board decided on June 5, 2026, that more time is needed to evaluate matters related to the meeting and the business to be presented.
The company has not set a new date and plans to announce the rescheduled date, time, and related details in a later SEC filing and other communications. A definitive proxy statement for the meeting has already been filed, and stockholders are encouraged to review the proxy materials available on the SEC’s website and the company’s site.
OSR Holdings, Inc. reported that it entered into an Asset Purchase Agreement with its indirect subsidiary Vaximm AG on May 27, 2026. The deal is a related party transaction and is designed to transfer outright ownership of intellectual property related to Vaximm’s programs from Vaximm to OSR Holdings.
This transfer aligns with a previously executed Global Exclusive License Agreement among OSR Holdings, Vaximm and BCM Europe AG covering VXM01, an oral DNA-based cancer immunotherapy. After the transfer, OSR Holdings will directly hold the underlying intellectual property and be the direct beneficiary of any future milestone and royalty payments arising from the license. The agreement includes customary representations, covenants, indemnification and confidentiality terms and is governed by Swiss law.
OSR Holdings, Inc. is calling an annual meeting on June 18, 2026 to vote on five proposals. Stockholders will elect seven directors, ratify the 2026 independent auditor, and cast an advisory say-on-pay vote on 2025 executive compensation.
The company also seeks approval to amend its 2025 Omnibus Incentive Plan, raising the share reserve from 6,300,000 to 8,000,000 shares, and to change its legal name to OSR Health, Inc.. Holders of 35,104,695 shares of common stock as of May 6, 2026 are entitled to one vote per share. The board unanimously recommends voting “FOR” all proposals.
OSR Holdings, Inc. filed an amended current report to add an independent fairness opinion on its related-party Global Exclusive License Agreement for cancer immunotherapy asset VXM01 with BCM Europe. The opinion concludes that up to $815 million in clinical, regulatory, and commercial milestones plus royalties are financially fair to OSR, Vaximm, and unaffiliated shareholders, based on a Monte Carlo median standalone asset value of about $93.4 million and a 40/60 licensor–licensee value split. The structure includes a 15% preferred return on any milestone shortfall recovered from downstream royalties, an option for OSR to issue up to $15 million of stock at $10.00 per share, and full pass-through of royalties after recovery. A contemplated blockchain-based TAC token royalty mechanism is explicitly excluded from the fairness conclusion.
OSR Holdings, Inc. entered a definitive global exclusive license agreement with its largest shareholder, BCM Europe AG, for VXM01, a Phase 3-ready oral immunotherapy targeting VEGFR-2. The structure includes potential milestone obligations of up to $815 million tied to VXM01’s development and commercialization.
To secure these obligations, BCM Europe and affiliates signed a Pledge Agreement, pledging their entire unencumbered OSR Holdings stake, representing about 29.7% of shares as of signing, as collateral. The deal also grants OSR Holdings a put option to require BCM Europe to buy up to $15 million of common stock at $10.00 per share, exercisable no earlier than six months after the agreement takes effect. The transaction is a related party deal and was approved by the Board, including independent directors, after an independent fairness opinion.
joint protein central, inc. filed a Schedule 13G reporting beneficial ownership of 2,603,759 shares of OSR Holdings, Inc. common stock, representing 7.9% of the class. The filing shows sole voting power over 2,603,759 shares and no dispositive power. The form is signed by Senyon Choe, Director on 04/22/2026.